



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MAGE-B4 (h2): 293T Lysate: sc-176213

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors, and based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens and are expressed in tumors of different histologic types, but not in normal tissues, with the exception of testis and placenta. Although a large number of MAGE genes have now been identified and extensively studied in tumors of various origin, their function in normal cells remains unknown.

REFERENCES

1. Okami, J., et al. 2000. Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. *Clin. Cancer Res.* 6: 2326-2332.
2. Granelli, P., et al. 2000. Melanoma antigen genes 1 and 2 are differentially expressed in human gastric and cardiac carcinomas. *Scand. J. Gastroenterol.* 35: 528-533.
3. Klein, C., et al. 2000. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. *J. Exp. Med.* 191: 1699-1708.
4. Busam, K.J., et al. 2000. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. *Mod. Pathol.* 13: 459-465.
5. Kobayashi, Y., et al. 2000. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. *J. Hepatol.* 32: 612-617.
6. Luiten, R., et al. 2000. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. *Tissue Antigens* 55: 149-152.
7. Osterlund, C., et al. 2000. Mage-B4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. *Cancer Res.* 60: 1054-1061.

CHROMOSOMAL LOCATION

Genetic locus: MAGEB4 (human) mapping to Xp21.2.

PRODUCT

MAGE-B4 (h2): 293T Lysate represents a lysate of human MAGE-B4 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

APPLICATIONS

MAGE-B4 (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive MAGE-B4 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.